Study of Linvoseltamab for high-risk MGUS or smoldering myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if linvoseltamab can remove abnormal plasma cells that might turn into multiple myeloma. It is for patients with high-risk MGUS (a precancerous condition) or non-high-risk smoldering myeloma who have not yet developed active myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have high-risk MGUS or non-high-risk smoldering multiple myeloma as defined by the study doctors.
- You should be able to care for yourself and do daily activities (ECOG score 0 or 1).
- Your blood counts and liver function must be within acceptable ranges.
- Your kidney function should be moderate or better (GFR at least 30 mL/min).
- You cannot have high-risk smoldering myeloma or any signs of active myeloma.
- You must not have other serious conditions like amyloidosis or Waldenström macroglobulinemia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called linvoseltamab against an existing treatment, daratumumab, for people with a high-risk form of smoldering multiple myeloma. The goal is to see which one works better to delay or prevent the disease from becoming active multiple myeloma.
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
This trial tests an immunotherapy drug combination for people newly diagnosed with multiple myeloma who have had some response to initial treatment but still have signs of disease. The goal is to see if this approach can help eliminate remaining cancer cells and potentially improve outcomes.
This trial tests if a lower dose of linvoseltamab can still work well for people with multiple myeloma that has come back or not responded to treatment. It aims to reduce side effects while keeping the cancer under control.
Hear when a new Monoclonal Gammopathy of Undetermined Significance (MGUS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.